Sam Chun Dang Pharm. Co. Ltd
Sam Chun Dang Pharm. Co., Ltd manufactures, distributes, imports, and exports pharmaceuticals in South Korea. It provides ophthalmology, cardiovascular, endocrinology, antibacterial, anti-fungal, antiviral, respiratory, anti-inflammatory, antihistamine, and musculoskeletal products, as well as vitamins and gastro intestine products. The company was founded in 1943 and is headquartered in Seoul, S… Read more
Sam Chun Dang Pharm. Co. Ltd (000250) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.044x
Based on the latest financial reports, Sam Chun Dang Pharm. Co. Ltd (000250) has a cash flow conversion efficiency ratio of -0.044x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-15.17 Billion) by net assets (₩343.90 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sam Chun Dang Pharm. Co. Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Sam Chun Dang Pharm. Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Sam Chun Dang Pharm. Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sam Chun Dang Pharm. Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wan Hai Lines Ltd
TW:2615
|
0.054x |
|
Swissquote Group Holding Ltd
PINK:SWQGF
|
N/A |
|
Sodexo SA
PA:SW
|
0.252x |
|
Hangzhou Silan Microelectronics Co Ltd
SHG:600460
|
0.067x |
|
MIRUM PHARMAC. DL-0001
F:08D
|
N/A |
|
Great-West Lifeco Inc 4.50% Non-Cum 1st Pfd Shs Ser I
PINK:GRWTF
|
-0.010x |
|
Globalstar Inc
NYSE MKT:GSAT
|
0.091x |
|
Lifco AB (publ)
PINK:LFCBY
|
0.103x |
Annual Cash Flow Conversion Efficiency for Sam Chun Dang Pharm. Co. Ltd (2012–2024)
The table below shows the annual cash flow conversion efficiency of Sam Chun Dang Pharm. Co. Ltd from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩266.11 Billion | ₩21.77 Billion | 0.082x | +4.22% |
| 2023-12-31 | ₩298.46 Billion | ₩23.43 Billion | 0.078x | +2.70% |
| 2022-12-31 | ₩173.74 Billion | ₩13.28 Billion | 0.076x | +272.65% |
| 2021-12-31 | ₩174.09 Billion | ₩-7.71 Billion | -0.044x | -354.23% |
| 2020-12-31 | ₩186.63 Billion | ₩3.25 Billion | 0.017x | -91.02% |
| 2019-12-31 | ₩157.87 Billion | ₩30.60 Billion | 0.194x | +15.00% |
| 2018-12-31 | ₩148.52 Billion | ₩25.03 Billion | 0.169x | -8.68% |
| 2017-12-31 | ₩141.34 Billion | ₩26.09 Billion | 0.185x | +30.05% |
| 2016-12-31 | ₩125.17 Billion | ₩17.76 Billion | 0.142x | -6.45% |
| 2015-12-31 | ₩114.32 Billion | ₩17.34 Billion | 0.152x | +8.38% |
| 2014-12-31 | ₩139.68 Billion | ₩19.55 Billion | 0.140x | +4.69% |
| 2013-12-31 | ₩119.23 Billion | ₩15.94 Billion | 0.134x | +622.90% |
| 2012-12-31 | ₩86.63 Billion | ₩1.60 Billion | 0.018x | -- |